CIK 0001752828 · <br>Emerging growth company
Celularity Inc
Sign in to watch- Ticker
- CELU
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831702591
- Phone
- (908) 768-2170
- Business address
- 170 PARK AVE, FLORHAM PARK, NJ, 07932
- Former names
- GX Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-13 | Glover Bradley Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +57,721 | 57,721 | ||
| 2022-04-13 | Jones Anne Chief Business Officer | Grant or award | +16,405 | 16,405 | ||
| 2022-04-13 | Jones Anne Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +48,100 | 48,100 | ||
| 2022-03-01 | STARR INTERNATIONAL CO INC 10% owner | Option exercise | +6,640,694 | $3.50 | $23.2M | 15,281,389 |
| 2022-03-01 | STARR INTERNATIONAL CO INC 10% owner | Option exercise · Warrant (Right to Buy) | −6,640,694 | 0 | ||
| 2021-11-16 | Jones Anne Chief Business Officer | Grant or award | +25,000 | 52,888 | ||
| 2021-11-16 | Glover Bradley See Remarks | Grant or award | +25,000 | 57,810 | ||
| 2021-11-16 | Glover Bradley See Remarks | Shares withheld for taxes | −3,734 | $1.89 | $7K | 54,076 |
| 2021-11-09 | VON ESCHENBACH ANDREW C. Director | Option exercise | +100,000 | $0.28 | $28K | 100,000 |
| 2021-11-09 | VON ESCHENBACH ANDREW C. Director | Option exercise · Stock Option (Right to Buy) | −100,000 | 207,437 | ||
| 2021-09-15 | Pecora Andrew L President | Grant or award · Stock Option (Right to Buy) | +2,469,282 | 2,469,282 | ||
| 2021-09-13 | Mirakhur Beloo EVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2021-09-09 | Brigido Stephen Pres, Functional Regeneration | Grant or award · Stock Option (Right to Buy) | +153,718 | 153,718 | ||
| 2021-09-09 | Smith Robin L Director | Grant or award · Stock Option (Right to Buy) | +56,053 | 56,053 | ||
| 2021-09-09 | Hariri Robert J Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +2,690,079 | 2,690,079 | ||
| 2021-09-09 | Diamandis Peter Director | Grant or award · Stock Option (Right to Buy) | +56,053 | 56,053 | ||
| 2021-09-09 | Mazur Marc Director | Grant or award · Stock Option (Right to Buy) | +56,053 | 56,053 | ||
| 2021-09-09 | Lim Kok Thay Director | Grant or award · Stock Option (Right to Buy) | +56,053 | 56,053 | ||
| 2021-09-09 | Dunn Keary General Counsel & EVP | Grant or award · Stock Option (Right to Buy) | +76,859 | 76,859 | ||
| 2021-09-09 | SCULLEY JOHN Director | Grant or award · Stock Option (Right to Buy) | +56,053 | 56,053 |
Page 12 of 15 · 299 trades